GENE ONLINE|News &
Opinion
Blog

2021-11-10| Special

Experts Weigh on How COVID Vaccine Development Has Prepared Us for the Next Pandemic

by Sahana Shankar
Share To
The COVID-19 pandemic was a major disruptive force to propel major innovation, scale, and capacity building in vaccine development. The last two years have seen an unprecedented acceleration in vaccine research, regulatory approvals, and consumer readiness. In a panel discussion titled “Future of Vaccines’,  at the Financial Times Global Pharmaceutical and Biotechnology Conference, industry experts shared their lessons from the COVID-19 pandemic.

The panel, moderated by Greg Reh, Global Life Sciences and Healthcare Industry leader, Deloitte, comprised of

Judy Stewart, Senior Vice President, Head of US vaccines, GlaxoSmithKline Lovisa Afzelius, Origination Partner, Flagship Pioneering Nell Beattie, Chief Business Officer, VBI Vaccines Rasmus Bech Hansen, Co-Founder, and CEO, Airfinity

It's free! Log in now to read

LATEST
Preventive Medicine for Neurodegeneration on the Rise: New Breakthrough in Routine Blood Testing for Alzheimer’s Disease
2024-05-20
Discrimination Leads to Rapid Aging, Science Shows the Detrimental Effects of this Act
2024-05-17
A New Study has Linked Treatment Resistant Depression to Body Mass Index
2024-05-16
AI Reveals Sex-Related Brain Differences and Precision Medicine Potential
2024-05-16
The EU Sustainability Directive’s Influence on Pharmaceutical Supply Chains
2024-05-15
New UC Berkeley Study Challenges Traditional Views on Lactate and Carbohydrate Metabolism
2024-05-15
First Person to Receive Transplanted Pig Kidney has Died
2024-05-13
EVENT
Scroll to Top